Search the Newsreel

Neogenomics stock hits 52-week high at 15.61 USD

NeoGenomics Inc. (NEO) stock reached a 52-week high of $15.61 USD, representing a 162.75% increase over the past year. Despite trading above its Fair Value, analysts are optimistic about the company turning profitable this year. This surge follows strong second-quarter 2026 earnings, where NeoGenomics …

NeoGenomics Reports Second Quarter 2026 Results

NeoGenomics, Inc. announced its second-quarter 2026 results, showing an 11% year-over-year increase in total revenue to $202 million, with robust clinical services revenue growth of 14% driven by a 26% increase in NGS revenue. The company reported a GAAP net income of $2 million …

Gamco Investors INC. ET AL Boosts Stock Holdings in NeoGenomics, Inc. $NEO

Gamco Investors INC. ET AL significantly increased its stake in NeoGenomics, Inc. by 525% in the first quarter, now holding 100,000 shares valued at $742,000. This move comes as NeoGenomics reported better-than-expected Q2 earnings and raised its fiscal 2026 revenue guidance, despite ongoing concerns …

Neogen Chemicals Limited Just Beat EPS By 69%: Here's What Analysts Think Will Happen Next

NeoGenomics (NASDAQ:NEO) Hits New 1-Year High After Better-Than-Expected Earnings

Why NeoGenomics (NEO) Stock Is Up Today

NeoGenomics Inc (NEO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Raised ...

NeoGenomics Inc (NEO) reported strong Q2 2026 results with an 11% year-over-year revenue growth to $201.7 million, driven by robust clinical and Next-Generation Sequencing (NGS) performance. The company raised its full-year 2026 revenue guidance to $802 million to $806 million and adjusted EBITDA guidance …

NeoGenomics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NEO) 2026-07-28

This article announces that NeoGenomics, Inc. published its Q2 2026 earnings call presentation. The company reported an EPS of $0.05, beating estimates by $0.02, and revenue of $201.66M, surpassing expectations by $4.67M and representing an 11.21% year-over-year increase. The presentation is related to their …

NeoGenomics anticipates $802M-$806M 2026 revenue as it targets mid-20% NGS growth and adjusts pharma expectations

Earnings Call Insights: NeoGenomics (NEO) Q2 2026 MANAGEMENT VIEW * "We're raising guidance because of these results as well as the underlying clinical strength we're seeing in the back half of this year." (CEO Anthony Zook) * "Total revenue in the quarter was $201.7 …

NeoGenomics (NASDAQ:NEO) Posts Earnings Results, Beats Expectations By $0.02 EPS

NeoGenomics (NASDAQ:NEO) reported quarterly earnings that surpassed analyst expectations, with an EPS of $0.05 against an estimated $0.03, and revenue of $201.66 million, exceeding the $196.93 million estimate. Despite the positive earnings surprise, the company posted a negative net margin and return on equity. …

Earnings call transcript: NeoGenomics tops Q2 2026 estimates and lifts outlook

NeoGenomics Inc. reported strong second-quarter 2026 earnings, surpassing Wall Street expectations for both profit and sales, driven by robust clinical and next-generation sequencing (NGS) business growth. The company raised its full-year 2026 revenue and adjusted EBITDA guidance, despite continued weakness in its non-clinical pharma …

Resultados trimestrales: NeoGenomics supera las previsiones con un beneficio por acción ajustado de 0,05 USD en el segundo trimestre

NeoGenomics Releases Q2 2026 Financial Results

NeoGenomics, Inc. reported strong Q2 2026 financial results, with adjusted EPS of $0.05, significantly beating analyst estimates, and revenue of $201.7M, surpassing consensus. The company saw an 11.2% increase in revenue year-over-year, primarily driven by its clinical services segment. Management provided full-year adjusted EPS …

NeoGenomics (NEO) Is Down 7.7% After DOJ Settlement On Legacy Agreements – Has The Bull Case Changed?

NeoGenomics recently finalized a civil settlement with the U.S. Department of Justice for nearly $10 million, resolving a compliance overhang after an internal investigation into past agreements. Despite a 7.7% stock drop, the settlement amount is manageable given prior reserves, and the company is …

EOG Resources (EOG) Expected to Announce Quarterly Earnings on Tuesday

EOG Resources (EOG) is anticipated to report its Q2 2026 earnings after market close on Tuesday, August 4th, with analysts forecasting $5.00 EPS and $8.00 billion in revenue. The company's previous quarter exceeded expectations, reporting $3.41 EPS against a $3.23 consensus and revenue of …

American Capital Management Inc. Trims Stock Position in Neogen Corporation $NEOG

American Capital Management Inc. significantly reduced its stake in Neogen Corporation (NASDAQ:NEOG) by 90.4% in the first quarter, selling over 1.2 million shares. Despite this, other institutional investors like JPMorgan Chase & Co. and Bessemer Group Inc. increased their holdings, with institutional investors now …

Empowered Funds LLC Cuts Stock Position in EOG Resources, Inc. $EOG

Empowered Funds LLC significantly decreased its stake in EOG Resources, Inc. (NYSE:EOG) by 5.0% during the first quarter, selling 15,666 shares. This adjustment leaves the firm holding 297,143 shares, valued at approximately $42.96 million. EOG Resources maintains a "Moderate Buy" consensus rating among analysts …

Energy Income Partners LLC Grows Holdings in EOG Resources, Inc. $EOG

Energy Income Partners LLC increased its stake in EOG Resources, Inc. by 28.0% during the first quarter, now owning 195,943 shares valued at $28.33 million. Other institutional investors also adjusted their positions in EOG, which has seen strong stock performance, positive quarterly earnings, and …

Cetera Investment Advisers Sells 15,142 Shares of EOG Resources, Inc. $EOG

Cetera Investment Advisers reduced its stake in EOG Resources (NYSE:EOG) by 9.6% in the first quarter, selling 15,142 shares and retaining 142,939 shares valued at $20.7 million. Despite this, institutional investors collectively own 89.91% of EOG. Analysts maintain a "Moderate Buy" rating with an …

Neogen (NEOG) Reports Q2: Everything You Need To Know Ahead Of Earnings

NeoGenomics | 10-Q: Q2 2026 Earnings Report

NeoGenomics’s (NASDAQ:NEO) Q2 CY2026: Beats On Revenue

NeoGenomics (NASDAQ:NEO) reported strong Q2 CY2026 results, exceeding Wall Street's expectations for revenue and adjusted EPS. The oncology diagnostics company's revenue grew 11.2% year-on-year to $201.7 million, with an adjusted EPS of $0.05. NeoGenomics also slightly raised its full-year revenue and adjusted EPS guidance, …

NEOGENOMICS ($NEO) Releases Q2 2026 Earnings, Stock Rises

EOG Resources (EOG) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

NeoGenomics pays $10 million to settle kickback allegations after self-disclosing below-market deals

NeoGenomics Laboratories has agreed to pay nearly $10 million to settle allegations that it violated the False Claims Act. The settlement comes after NeoGenomics self-disclosed providing below-market-value consulting services to healthcare providers who referred patients for laboratory testing and paying variable referral-based compensation to …

EOG|EOG Resources Inc|Price:140.290|Chg%:-6.100

This article provides an in-depth analysis of EOG Resources Inc. (EOG), covering its current market trends, real-time quotes, and various financial metrics. It highlights the company's strong fundamentals, high growth potential, and fair valuation, alongside a "Buy" rating from analysts with a target price …

First Light Asset Management LLC Has $72.20 Million Position in NeoGenomics, Inc. $NEO

First Light Asset Management LLC slightly reduced its stake in NeoGenomics, Inc. by 3% in Q1, but it remains its third-largest position, valued at $72.2 million. NeoGenomics, a cancer-focused genetic testing provider, reported strong Q1 revenue growth of 11.3% year-over-year but remains unprofitable. Analyst …

Neogen Corp (NEOG) Cash Flow

This article provides a detailed historical cash flow statement for Neogen Corp (NEOG), including operating, investing, and financing cash flows, presented quarterly and annually. It outlines key cash flow metrics such as net income, operating gains/losses, deferred tax, changes in working capital, capital expenditures, …

Understanding the Setup: (EOG) and Scalable Risk

This article analyzes Eog Resources Inc. (NYSE: EOG), highlighting strong sentiment across all horizons and an exceptional 35.3:1 risk-reward setup targeting a 10.2% gain against 0.3% risk. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with a multi-timeframe signal analysis to …

Neogen Corp (NEOG) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an historical overview of dividends and stock splits for Neogen Corp (NEOG). It notes that Neogen has not distributed any dividends in the past five years. The company has had one recorded stock split event, a 1-for-2 split on May 12, …

NEO|Neogenomics Inc|Price:13.890|Chg%:-0.350

This article provides an overview of Neogenomics Inc (NEO) stock performance and basic financial information. It shows the current stock price, market cap, and a note that a stock score is unavailable due to insufficient data. The article also mentions various sections like Financials, …

Healthcare of Ontario Pension Plan Trust Fund Sells 193,454 Shares of Neogen Corporation $NEOG

The Healthcare of Ontario Pension Plan Trust Fund reduced its stake in Neogen Corporation by 5.5% in the first quarter, selling 193,454 shares and now owning 3,297,346 shares valued at $30.63 million. Despite this, other institutional investors like Huntington National Bank and ProShare Advisors …

NEO Income Statement

This article from TradingKey provides an overview of Neogenomics Inc.'s (NEOUSD) income statement. It explains how to interpret quarterly and annual financial data, defines key metrics like YOY, and highlights important figures such as revenue, gross profit, operating profit, and EPS for stock analysis. …

Neogen Chemicals releases Q1FY27 earnings call recording for stakeholder review

Neogen Chemicals Publishes Q1 FY27 Earnings Presentation for Investors

Neogen Chemicals revenue rises 37% in Q1FY27 as battery expansion plans take shape